Trial Profile
Multicenter Trials to Evaluate the Efficacy and Toxicity of Sirolimus/Tacrolimus Combination as a GVHD Prophylaxis After HLA Matched Related PBSCT.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Tacrolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 02 Apr 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
- 26 Oct 2013 Additional lead trial centres added as reported by ClinicalTrials.gov.
- 16 Mar 2013 Additional lead trial centres added as reported by ClinicalTrials.gov.